• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

byConstance Wu
November 2, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized study comparing the efficacy of rivaroxaban with warfarin, dose-adjusted rivaroxaban treatment resulted in near doubling of risk for recurrent thrombosis.

2. The two treatment groups experienced similar bleeding outcomes, but patients in the rivaroxaban group had a higher stroke incidence rate.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Antiphospholipid Antibody Syndrome (APS) is a rare thrombophilic disorder treated primarily through long-term anticoagulation with vitamin K antagonists (VKA). However, this method has several notable disadvantages, including the need for frequent monitoring, the likelihood of food and drug interactions, and the increased risk of bleeding complications. With the advent of novel anticoagulation therapies, it is necessary to reevaluate whether this strategy ought to remain a mainstay amongst numerous alternatives. In this open-label noninferiority study, rivaroxaban failed to demonstrate noninferiority to warfarin for thrombotic APS, showing a non-statistically significant near doubling of risk for recurrent thrombosis. These findings were consistent with a previous rivaroxaban noninferiority study that showed not only a higher rate of thrombotic events but also a greater frequency of occurrence in arterial circulation. Additionally, stroke incidence was substantially higher in the rivaroxaban group. Limitations of this study included failure to assess anticoagulation intensity, reliance on exploratory post hoc analyses, and a small sample size with insufficient power to detect differences between patient subgroups.

Click to read the study in Annals of Internal Medicine

Click to read an accompanying editorial in Annals of Internal Medicine

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

TRAPS: Rivaroxaban vs. Warfarin for Secondary Prevention in Antiphospholipid Syndrome [Classics Series]

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

Tags: antiphosholipid syndromeAntiphospholipid Antibody Syndromecoumadindirect oral anticoagulant (DOAC)rivaroxaban
Previous Post

The ORIP trial: n-3 polyunsaturated long chain fatty acid supplementation has no effect on preterm delivery rate

Next Post

Association between parental income during childhood and risk of schizophrenia later in life

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

TRAPS: Rivaroxaban vs. Warfarin for Secondary Prevention in Antiphospholipid Syndrome [Classics Series]

June 23, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

June 21, 2022
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

April 19, 2022
#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
StudyGraphics

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 26, 2022
Next Post
Quick Take: Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children

Association between parental income during childhood and risk of schizophrenia later in life

Peanut allergy effectively treated with oral immunotherapy: the PALISADE trial

Effectiveness of clinical decision support tools on pediatrician adherence to peanut allergy prevention guidelines

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Association of body mass index and extreme obesity with long-term outcomes following percutaneous coronary intervention

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Remdesivir does not reduce mortality in ventilated patients with COVID-19
  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.